Home
/
IGC Pharma, Inc.
/
Financials
/
Quarterly
IGC Pharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that IGC Pharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Sep 30, 2025
$191.0K
Nov 14, 2025
Q1
2026
Jun 30, 2025
$328.0K
Aug 14, 2025
Q3
2025
Dec 31, 2024
$257.0K
Feb 14, 2025
Q2
2026
Sep 30, 2024
$412.0K
Nov 14, 2025
Q1
2026
Jun 30, 2024
$272.0K
Aug 14, 2025
Q3
2025
Dec 31, 2023
$204.0K
Feb 14, 2025
Q2
2025
Sep 30, 2023
$291.0K
Nov 12, 2024
Q1
2025
Jun 30, 2023
$555.0K
Aug 7, 2024
Q1
2024
Mar 31, 2023
$212.0K
Aug 10, 2023
Q3
2024
Dec 31, 2022
$332.0K
Feb 14, 2024
Q2
2024
Sep 30, 2022
$202.0K
Nov 9, 2023
Q1
2024
Jun 30, 2022
$212.0K
Aug 10, 2023
Q3
2023
Dec 31, 2021
$142.0K
Feb 14, 2023
Q2
2023
Sep 30, 2021
$56.0K
Nov 1, 2022
Q1
2023
Jun 30, 2021
$77.0K
Aug 5, 2022
Q3
2022
Dec 31, 2020
$108.0K
Feb 10, 2022
Q2
2022
Sep 30, 2020
$125.0K
Oct 29, 2021
Q1
2022
Jun 30, 2020
$584.0K
Aug 11, 2021
Q3
2021
Dec 31, 2019
$573.0K
Feb 16, 2021
Q2
2021
Sep 30, 2019
$1.82M
Nov 20, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Sep 30, 2025
($1.82M)
Nov 14, 2025
Q1
2026
Jun 30, 2025
($1.60M)
Aug 14, 2025
Q3
2025
Dec 31, 2024
($1.83M)
Feb 14, 2025
Q2
2026
Sep 30, 2024
($1.72M)
Nov 14, 2025
Q1
2026
Jun 30, 2024
($2.38M)
Aug 14, 2025
Q3
2025
Dec 31, 2023
($5.59M)
Feb 14, 2025
Q2
2025
Sep 30, 2023
($2.45M)
Nov 12, 2024
Q1
2025
Jun 30, 2023
($2.08M)
Aug 7, 2024
Q3
2024
Dec 31, 2022
($2.25M)
Feb 14, 2024
Q2
2024
Sep 30, 2022
($2.44M)
Nov 9, 2023
Q1
2024
Jun 30, 2022
($2.79M)
Aug 10, 2023
Q3
2023
Dec 31, 2021
($2.38M)
Feb 14, 2023
Q2
2023
Sep 30, 2021
($4.34M)
Nov 1, 2022
Q1
2023
Jun 30, 2021
($1.79M)
Aug 5, 2022
Q3
2022
Dec 31, 2020
($2.32M)
Feb 10, 2022
Q2
2022
Sep 30, 2020
($1.66M)
Oct 29, 2021
Q1
2022
Jun 30, 2020
($1.88M)
Aug 11, 2021
Q3
2021
Dec 31, 2019
($1.60M)
Feb 16, 2021
Q2
2021
Sep 30, 2019
($1.18M)
Nov 20, 2020
Q1
2021
Jun 30, 2019
($1.38M)
Aug 19, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2026
Sep 30, 2025
($2.90M)
Nov 14, 2025
Q1
2026
Jun 30, 2025
($1.91M)
Aug 14, 2025
Q3
2025
Dec 31, 2024
($1.88M)
Feb 14, 2025
Q2
2026
Sep 30, 2024
($1.76M)
Nov 14, 2025
Q1
2026
Jun 30, 2024
($2.40M)
Aug 14, 2025
Q3
2025
Dec 31, 2023
($3.00M)
Feb 14, 2025
Q2
2025
Sep 30, 2023
($2.49M)
Nov 12, 2024
Q1
2025
Jun 30, 2023
($2.14M)
Aug 7, 2024
Q3
2024
Dec 31, 2022
($2.28M)
Feb 14, 2024
Q2
2024
Sep 30, 2022
($2.49M)
Nov 9, 2023
Q1
2024
Jun 30, 2022
($2.80M)
Aug 10, 2023
Q3
2023
Dec 31, 2021
($2.39M)
Feb 14, 2023
Q2
2023
Sep 30, 2021
($4.35M)
Nov 1, 2022
Q1
2023
Jun 30, 2021
($2.19M)
Aug 5, 2022
Q3
2022
Dec 31, 2020
($2.33M)
Feb 10, 2022
Q2
2022
Sep 30, 2020
($1.68M)
Oct 29, 2021
Q1
2022
Jun 30, 2020
($1.93M)
Aug 11, 2021
Q3
2021
Dec 31, 2019
($1.68M)
Feb 16, 2021
Q2
2021
Sep 30, 2019
($1.29M)
Nov 20, 2020
Q1
2021
Jun 30, 2019
($1.46M)
Aug 19, 2020